Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors
Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors
Significance of gut microbiota in patients receiving CAR T cell immunotherapy
Cancer medicine shortages for children around the world
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM
Latest in combination therapy for NDMM patients
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies